Targeted therapies are main focus in NSCLC pipeline.
By Hardik Patel, Lead Analyst
25 September 2014
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
Targeted therapies continue to flourish in the non-small cell lung cancer (NSCLC) market as molecular profiling has become more prominent as a guide for treatment decisions. Products currently in development for NSCLC focus on treating patients with new cancer-driving mutations as well as treating patients who have acquired resistance to established targeted therapies. The arrival of new targeted therapies will further segment the NSCLC population and provide more personalized treatment regimens for various patient subgroups.
Datamonitor Healthcare has reviewed candidates in development for NSCLC across the US, Japan, and five major EU markets to highlight key trends and to provide an analysis of clinical trial design, innovative early-phase projects, and future treatment approaches.
How will our NSCLC pipeline report benefit you?
- Identify early-phase opportunities
Access our exclusive interactive early-phase forecast model as well as an in-depth analysis of key modes of action, enabling you to identify any investment opportunities within the pipeline.
- Unmet needs
Improve your chances of success in the NSCLC market by recognizing current unmet needs and addressing the key factors that novel therapeutics will have to focus on in order to obtain a successful standing within the market.
- Future of treatment
Understand how appropriate clinical trial design and the development of companion diagnostics will determine the success of personalized therapies in the NSCLC market, allowing you to govern your product’s future success.
Key questions answered
- How will therapies targeting the PD-1 pathway change treatment algorithms within NSCLC?
- What drugs have been recently discontinued and what factors contributed to this decision?
- How will the emergence of new oncogenic mutations affect patient segments targeted by the early-phase pipeline?
|Drug List:||Companies Mentioned:|
Posted in Oncology.